未登录

A

Anders Josefsson

Institute of Clinical Sciences

H指数:15

被引数:923

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Monte Carlo microdosimetry of 211at in multi-species thyroid follicle models: AlfaMC versus MCNPX and Geant4

多物种甲状腺滤泡模型中211At的蒙特卡罗微观剂量学：AlfaMC与MCNPX和Geant4的比较

IF3.2

2026-08-150

OA

Evaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents

NUCLEAR MEDICINE AND BIOLOGY

IF3

2024-01-014

OAAI

Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents

IF4.3

2023-11-085

OAAI

Early Normal Tissue Effects and Bone Marrow Relative Biological Effectiveness for an Actinium 225-Labeled HER2/neu-Targeting Antibody

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2023-11-012

OAAI

Bone Marrow Relative Biological Effectiveness for a 212Pb-labeled Anti-HER2/neu Antibody

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2023-02-012

OAAI

Prostate Specific Antigen and Biopsy Contamination in the Goteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial

JOURNAL OF UROLOGY

IF6.8

2022-11-013

PRE

Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2022-07-096

OA

Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered a-Particles May Realize the Promise for 225Ac in Large, Solid Tumors

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-11-186

OA

Two diverse carriers are better than one: A case study in α-particle therapy for prostate specific membrane antigen-expressing prostate cancers

BIOENGINEERING & TRANSLATIONAL MEDICINE

IF5.7

2021-11-178

OAAI

Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2021-06-1215

PREAI

Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2020-11-2721

OAAI

Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma

NUCLEAR MEDICINE AND BIOLOGY

IF3

2020-09-0123

OAAI

RBE, in vivo, for a 212Pb-conjugated anti-HER2/neu antibody

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Accuracy in dosimetry of diagnostic agents: impact of the number of source tissues used in whole organ S value-based calculations

EJNMMI RESEARCH

IF3

2020-03-192

OAAI

Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer

IF13.3

2020-01-0123

OAAI

Advances in Small Scale Modeling of Bone Marrow Dosimetry for Targeted 223Ra Therapy and the Potential for Treatment Planning

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-010

OAAI

Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2019-06-2855

OAAI

Development of peptide-based targeted α-therapy for triple negative breast cancer

CANCER RESEARCH

IF16.6

2019-02-150

PRE

Re-evaluation of pediatric 18F-FDG dosimetry: Cristy-Eckerman versus UF/NCI hybrid computational phantoms

PHYSICS IN MEDICINE AND BIOLOGY

IF3.4

2018-08-149

OAAI

Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2018-02-0911

OAAI